BioCryst shareholders reject planned merger with Idera

11 July 2018

The announcement on January 22 this year that US biotech firms BioCryst Pharmaceuticals (Nasdaq: BCRX) and Idera Pharmaceuticals (Nasdaq: IDRA) were merging did not go down well with investors, with their shares plunging by as much as 12% and 28%, respectively.

Now the merger has been called off, seeing BioCryst shares rally 7.5% after hours, following flat trade Tuesday to close at $6.14, while Idera shares dropped 16% after hours.

The merger agreement was terminated following the July 10, 2018 special meeting of BioCryst stockholders at which its shareholders voted against the proposed mergers. Separately, a majority of Idera’s stockholders voted in favor of the adoption of the agreement at a special meeting of Idera stockholders, also held on July 10, 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK